RA Capital Management’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q2 | – | Sell |
-8,659,983
| Closed | -$70.5M | – | 26 |
|
|
2019
Q1 | $70.5M | Sell |
8,659,983
-2,000,366
| -19% | -$16.3M | 3.04% | 10 |
|
|
2018
Q4 | $86M | Buy |
10,660,349
+1,425,657
| +15% | +$11.5M | 5.01% | 5 |
|
|
2018
Q3 | $70.5M | Buy |
9,234,692
+2,250,000
| +32% | +$17.2M | 3.77% | 7 |
|
|
2018
Q2 | $40M | Hold |
6,984,692
| – | – | 2.6% | 15 |
|
|
2018
Q1 | $33.3M | Hold |
6,984,692
| – | – | 2.55% | 13 |
|
|
2017
Q4 | $34.3M | Hold |
6,984,692
| – | – | 2.87% | 12 |
|
|
2017
Q3 | $36.6M | Buy |
6,984,692
+1,822,450
| +35% | +$9.55M | 3.31% | 11 |
|
|
2017
Q2 | $28.7M | Buy |
5,162,242
+1,672,447
| +48% | +$9.3M | 3.29% | 10 |
|
|
2017
Q1 | $29.3M | Buy |
3,489,795
+500,000
| +17% | +$4.2M | 3.6% | 6 |
|
|
2016
Q4 | $18.9M | Hold |
2,989,795
| – | – | 2.68% | 10 |
|
|
2016
Q3 | $13.2M | Hold |
2,989,795
| – | – | 1.36% | 17 |
|
|
2016
Q2 | $8.49M | Hold |
2,989,795
| – | – | 1.18% | 19 |
|
|
2016
Q1 | $8.46M | Sell |
2,989,795
-104,269
| -3% | -$295K | 1.08% | 26 |
|
|
2015
Q4 | $31.9M | Buy |
3,094,064
+1,897,461
| +159% | +$19.6M | 3.16% | 8 |
|
|
2015
Q3 | $13.6M | Sell |
1,196,603
-1,408,758
| -54% | -$16.1M | 1.96% | 19 |
|
|
2015
Q2 | $38.9M | Sell |
2,605,361
-4,321,256
| -62% | -$64.5M | 3.91% | 7 |
|
|
2015
Q1 | $62.5M | Sell |
6,926,617
-123,739
| -2% | -$1.12M | 6.21% | 3 |
|
|
2014
Q4 | $85.7M | Sell |
7,050,356
-18,803
| -0.3% | -$229K | 9.21% | 1 |
|
|
2014
Q3 | $69.1M | Buy |
7,069,159
+3,870,630
| +121% | +$37.9M | 8.17% | 2 |
|
|
2014
Q2 | $40.8M | Sell |
3,198,529
-1,148,927
| -26% | -$14.6M | 4.12% | 7 |
|
|
2014
Q1 | $46M | Hold |
4,347,456
| – | – | 3.3% | 10 |
|
|
2013
Q4 | $33M | Sell |
4,347,456
-1,497,244
| -26% | -$11.4M | 3.85% | 8 |
|
|
2013
Q3 | $42.5M | Buy |
+5,844,700
| New | +$42.5M | 4.44% | 8 |
|